CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
| Revenue (Most Recent Fiscal Year) | $1.54M |
| Net Income (Most Recent Fiscal Year) | $-258.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.18 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -190220.86% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -52.35% |
| Return on Assets (Trailing 12 Months) | -47.61% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.82 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.82 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.93 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.94 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.90 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.35 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 78.53M |
| Free Float | 74.45M |
| Market Capitalization | $2.27B |
| Average Volume (Last 20 Days) | 2.44M |
| Beta (Past 60 Months) | 0.90 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.20% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |